Mirtazapin Teva B.V (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine, and by antagonising postsynaptic 5‑HT2, 5‑HT3 and H1 receptors. This dual action enhances serotonergic and noradrenergic neurotransmission while providing sedative and appetite‑stimulating effects.

The appropriate dose of mirtazapine is determined individually by the prescribing clinician based on the patient’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Mirtazapine is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but insufficient human data. It should be used during pregnancy only if the potential benefit justifies the risk. Breastfeeding is not recommended unless the benefit outweighs potential infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined noradrenergic and serotonergic activity and strong antihistamine effect. This profile often results in pronounced sedation and weight gain, which can be advantageous for patients with insomnia or loss of appetite, but may be less suitable for those concerned about these side effects.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mirtazapin Teva B.V is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious risks include the potential for agranulocytosis or severe neutropenia, seizures, hepatic dysfunction, and rare but severe hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, liver abnormalities, or allergic reactions, and the drug should be discontinued if these occur.

Mirtazapin Teva B.V should be avoided in patients with known hypersensitivity to mirtazapine or any of its excipients, those currently taking monoamine oxidase inhibitors, and individuals with severe hepatic impairment unless the prescriber determines that benefits outweigh risks.